VAXATO 15 MG ( RIVAROXABAN ) 30 TABLETS

VAXATO 15 MG ( RIVAROXABAN ) 30 TABSLETS
Rivaroxaban FDA Approved Indications:

– Nonvalvular Atrial Fibrillation: 15 or 20 mg, once daily with food

– Treatment of DVT and/or PE: 15 mg orally twice daily with food for the first 21 days followed by 20 mg orally

once daily with food for the remaining treatment

– Reduction in the Risk of Recurrence of DVT and/or PE in patients at continued risk for DVT and/or PE: 10 mg

once daily with or without food, after at least 6 months of standard anticoagulant treatment

– Prophylaxis of DVT Following Hip or Knee Replacement Surgery: 10 mg orally once daily with or without food

– Prophylaxis of VTE in Acutely Ill Medical Patients at Risk for Thromboembolic Complications Not at High Risk

of Bleeding: 10 mg once daily, with or without food, in hospital and after hospital discharge for a total

recommended duration of 31 to 39 days

Mode of action

Vaxato is a highly selective direct factor Xa inhibitor with oral bioavailability. Inhibition of factor Xa interrupts the intrinsic and extrinsic pathway of the blood coagulation cascade, inhibiting both thrombin formation and development of thrombi. Rivaroxaban does not inhibit thrombin (activated factor II) and no effects on platelets have been demonstrated.

Package and Storage

Vaxato® 10mg

10 tablet

Store below 30°C in a dry place

Vaxato® 15mg

30 tablet

Store below 30°C in a dry place

Vaxato® 20mg

30 tablet

Store below 30°C in a dry place